The Journal of allergy and clinical immunology · 2025
Effects of inflammatory endotypes on disease trajectory in chronic rhinosinusitis with nasal polyps.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dorismond Christina, Trivedi Yash, Krysinski Mason R, Lubner Rory J, Huang Li-Ching, Goswami Sandeep, Sheng Quanhu, Chandra Rakesh K, Chowdhury Naweed I, Turner Justin H
Аннотация
BACKGROUND: Although phenotypic features have traditionally guided treatment in chronic rhinosinusitis, recent research has favored categorization on the basis of inflammatory endotype. However, the impact of endotypic differeces on clinical outcomes remains largely unknown.
OBJECTIVE: We sought to compare disease trajectory, primarily time-to-polyp recurrence, between chronic rhinosinusitis with nasal polyp (CRSwNP) endotypes.
METHODS: Samples were obtained from patients with CRSwNP undergoing surgery between 2015 and 2023, and cytokine levels were measured using a multiplex bead assay. Principal-component analysis followed by hierarchical cluster analysis was used to identify endotype clusters. Clinical outcomes were subsequently compared between clusters.
RESULTS: Six CRSwNP disease clusters were identified among the 269 included patients. Cluster 1 (46.5%) was characterized by relatively low inflammation. Cluster 4 (13.3%) and cluster 6 (7.1%) also exhibited low inflammation but with elevated levels of IL-12/IL-21 and CCL5, respectively. Cluster 2 (4.5%) represented a mixed type 1/3 inflammatory endotype (IFN-γHigh/IL-4High/IL-17AHigh), and cluster 3 (10.0%) was characterized by an innate, proinflammatory response (IL-1βHigh/IL-6High/IL-8High). Cluster 5 (18.9%) exhibited type 2-dominant inflammation (IL-5High/IL-9High/IL-13High). When comparing disease trajectory, cluster 2 (IFN-γHigh/IL-4High/IL-17AHigh) and cluster 4 (IL-12High/IL-21High) had the shortest time-to-polyp recurrence, whereas cluster 3 (IL-1βHigh/IL-6High/IL-8High) demonstrated the longest time-to-recurrence (P < .001). Time-to-oral steroid course (P = .13) and time-to-biologic therapy (P = .43) were similar across clusters.
CONCLUSIONS: The study highlights the heterogeneous nature of CRSwNP and differences in disease trajectory between endotypes, notably that patients with mixed type 1 and type 3 inflammation demonstrate more recalcitrant disease. These findings suggest that therapies beyond traditional type 2 inflammation treatments may be needed to effectively reduce CRSwNP disease recurrence.
OBJECTIVE: We sought to compare disease trajectory, primarily time-to-polyp recurrence, between chronic rhinosinusitis with nasal polyp (CRSwNP) endotypes.
METHODS: Samples were obtained from patients with CRSwNP undergoing surgery between 2015 and 2023, and cytokine levels were measured using a multiplex bead assay. Principal-component analysis followed by hierarchical cluster analysis was used to identify endotype clusters. Clinical outcomes were subsequently compared between clusters.
RESULTS: Six CRSwNP disease clusters were identified among the 269 included patients. Cluster 1 (46.5%) was characterized by relatively low inflammation. Cluster 4 (13.3%) and cluster 6 (7.1%) also exhibited low inflammation but with elevated levels of IL-12/IL-21 and CCL5, respectively. Cluster 2 (4.5%) represented a mixed type 1/3 inflammatory endotype (IFN-γHigh/IL-4High/IL-17AHigh), and cluster 3 (10.0%) was characterized by an innate, proinflammatory response (IL-1βHigh/IL-6High/IL-8High). Cluster 5 (18.9%) exhibited type 2-dominant inflammation (IL-5High/IL-9High/IL-13High). When comparing disease trajectory, cluster 2 (IFN-γHigh/IL-4High/IL-17AHigh) and cluster 4 (IL-12High/IL-21High) had the shortest time-to-polyp recurrence, whereas cluster 3 (IL-1βHigh/IL-6High/IL-8High) demonstrated the longest time-to-recurrence (P < .001). Time-to-oral steroid course (P = .13) and time-to-biologic therapy (P = .43) were similar across clusters.
CONCLUSIONS: The study highlights the heterogeneous nature of CRSwNP and differences in disease trajectory between endotypes, notably that patients with mixed type 1 and type 3 inflammation demonstrate more recalcitrant disease. These findings suggest that therapies beyond traditional type 2 inflammation treatments may be needed to effectively reduce CRSwNP disease recurrence.